Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 27, 2017

ICL evaluates pembrolizumab for rare pregnancy cancer

Researchers at Imperial College London (ICL) have evaluated immunotherapy drug pembrolizumab in a small clinical trial for the treatment of cancerous forms of gestational trophoblastic disease (GTD).

Researchers at Imperial College London (ICL) have evaluated immunotherapy drug pembrolizumab in a small clinical trial for the treatment of cancerous forms of gestational trophoblastic disease (GTD).

GTD is characterised by abnormal cells or tumours, which begin from womb cells that usually give rise to placenta, while pembrolizumab is designed to trigger the immune system of the body to target and destroy cancer cells.

Results showed that remission was achieved following treatment in three out of four subjects aged 37-47 with multi-drug resistant cancerous GTD.

The trial was carried out at Imperial College Healthcare NHS Trust’s Charing Cross Hospital and at the Department of Women’s and Children’s Health in Stockholm.

Patients were administered with intravenous pembrolizumab every three weeks for six months.

“The current treatments to tackle GTD cure most cases of the disease.”

It was observed that pembrolizumab was well-tolerated and the participants are reported to not display signs of cancer recurrence for five months to more than two years at follow up.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The researchers expect that the drug could potentially result in a 100% cure rate for women with drug-resistant GTD.

ICL professor Michael Seckl said: “The current treatments to tackle GTD cure most cases of the disease.

“However, there are a small number of women whose cancers are resistant to conventional therapies and as a result have a fatal outcome.

“Immunotherapy may be a life-saving treatment and can be used as an alternative to the much more toxic high-dose chemotherapy that is currently used.”

The team intends to further evaluate the effects of pembrolizumab on fertility to determine its use during early treatment stages.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU